Skip to main content

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Publisher: Bentham Science Publishers

Volume 7, Number 4, June 2007

Articles

The PI3K/Akt Pathway and Its Downstream Transcriptional Factors as Targets for Chemoprevention
pp. 305-316(12)
Authors: Zhang, Xinhai; Jin, Boquan; Huang, Chuanshu

Favourites:
ADD

AP-1 a Target for Cancer Prevention
pp. 317-324(8)
Authors: Matthews, Connie P.; Colburn, Nancy H.; Young, Matthew R.

Favourites:
ADD

ATM-NF-κB Connection as a Target for Tumor Radiosensitization
pp. 335-342(8)
Authors: Mokim Ahmed, Kazi; Jian Li, Jian

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

Hsp90: A Novel Target for the Disruption of Multiple Signaling Cascades
pp. 369-388(20)
Authors: Bishop, Stephanie C.; Burlison, Joseph A.; J. Blagg, Brian S.

Favourites:
ADD

Combining Radiation and Cancer Gene Therapy: A Potential Marriage of Physical and Biological Targeting?
pp. 389-409(21)
Authors: Hingorani, M.; White, C. L.; Agrawal, V. K.; Vidal, L.; Melcher, A.; Harrington, K. J.

Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more